JACK LIEBERMAN, M.D.; CHARLES MITTMAN, M.D.
To the editor: Welch and associates (Ann Intern Med 71:533-542, 1969) present data that suggest to them that individuals with intermediate levels of antitrypsin activity (heterozygotes) are not predisposed to develop pulmonary disease, unlike those with the homozygous deficiency. Their arguments, which are based upon statistical and clinical observations, must be questioned. First, the small number of heterozygotes discovered in their normal control population does not allow for a reliable statistical comparison with the number found in the pulmonary disease group. Secondly, their paper does not state the actual number of emphysema patients in their heterogeneous chest disease group, although
LIEBERMAN J, MITTMAN C. More on Antitrypsin Activity in Lung Disease. Ann Intern Med. ;72:437–439. doi: 10.7326/0003-4819-72-3-437_4
Download citation file:
Published: Ann Intern Med. 1970;72(3):437-439.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use